The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis

Cytokine

Volumn 74, Issue 1, 2015, Pages 43-53

  Paulissen, Sandra M J ^a   van Hamburg, Jan Piet ^a   Dankers, Wendy ^a   Lubberts, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune disease; CCR6; Plasticity; Rheumatoid arthritis; Th17

Indexed keywords

BRODALUMAB; CD161 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 26; INTERLEUKIN 8; IXEKIZUMAB; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SECUKINUMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; USTEKINUMAB; CCR6 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; RORC PROTEIN, HUMAN;

CELL ACTIVATION; CELL MEMBRANE DEPOLARIZATION; CELL METABOLISM; CYTOKINE PRODUCTION; EFFECTOR CELL; FIBROBLAST; HUMAN; IMMUNOMODULATION; LEUKOCYTE MIGRATION; MACROPHAGE; MACROPHAGE MIGRATION; MEMORY T LYMPHOCYTE; MOLECULAR PATHOLOGY; MONOCYTE; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; T LYMPHOCYTE SUBPOPULATION; TH17 1 CELL; TH17 CELL; TH22 CELL; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOSYNTHESIS; CELL PLASTICITY; GENETICS; IMMUNOLOGY; METABOLISM; MICROFLORA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CELL PLASTICITY; HUMANS; INTERLEUKIN-17; MICROBIOTA; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; RECEPTORS, CCR6; TH17 CELLS;

EID: 84930181101     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.002     Document Type: Review

References (149)

1. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672.
2. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
3. Isaacs J.D. The changing face of rheumatoid arthritis: sustained remission for all?. Nat Rev Immunol 2010, 10:605-611.
4. Cope A.P. T cells in rheumatoid arthritis. Arthritis Res Ther 2008, 10(Suppl 1):S1.
5. Lubberts E. Role of T lymphocytes in the development of rheumatoid arthritis. Implications for treatment. Curr Pharm Des 2014.
6. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545.
7. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
8. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
9. Kirkham B.W., Lassere M.N., Edmonds J.P., Juhasz K.M., Bird P.A., Lee C.S., et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131.
10. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7. R784-95.
11. Gaffen S.L., Jain R., Garg A.V., Cua D.J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014, 14:585-600.
12. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-646.
13. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
14. van Hamburg J.P., Asmawidjaja P.S., Davelaar N., Mus A.M., Colin E.M., Hazes J.M., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011, 63:73-83.
15. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62:2876-2885.
16. Nistala K., Moncrieffe H., Newton K.R., Varsani H., Hunter P., Wedderburn L.R. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008, 58:875-887.
17. Paulissen S.M., van Hamburg J.P., Davelaar N., Asmawidjaja P.S., Hazes J.M., Lubberts E. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J Immunol 2013, 191:1364-1372.
18. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871.
19. Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014, 211:89-104.
20. Maggi L., Santarlasci V., Capone M., Rossi M.C., Querci V., Mazzoni A., et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol 2012, 42:3180-3188.
21. Basu R., Hatton R.D., Weaver C.T. The Th17 family: flexibility follows function. Immunol Rev 2013, 252:89-103.
22. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
23. Baba M., Imai T., Nishimura M., Kakizaki M., Takagi S., Hieshima K., et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997, 272:14893-14898.
24. Liao F., Rabin R.L., Smith C.S., Sharma G., Nutman T.B., Farber J.M. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 1999, 162:186-194.
25. Hirota K., Yoshitomi H., Hashimoto M., Maeda S., Teradaira S., Sugimoto N., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007, 204:2803-2812.
26. Yang Y., Torchinsky M.B., Gobert M., Xiong H., Xu M., Linehan J.L., et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 2014, 510:152-156.
27. Yang J., Sundrud M.S., Skepner J., Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci 2014.
28. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
29. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
30. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
31. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3:811-821.
32. Starnes T., Robertson M.J., Sledge G., Kelich S., Nakshatri H., Broxmeyer H.E., et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001, 167:4137-4140.
33. Ely L.K., Fischer S., Garcia K.C. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009, 10:1245-1251.
34. Zrioual S., Ecochard R., Tournadre A., Lenief V., Cazalis M.A., Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009, 182:3112-3120.
35. Hot A., Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011, 70:727-732.
36. Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007, 282:13447-13455.
37. Sabat R., Ouyang W., Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014, 13:21-38.
38. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J., et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000, 275:31335-31339.
39. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011, 12:383-390.
40. Hor S., Pirzer H., Dumoutier L., Bauer F., Wittmann S., Sticht H., et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 2004, 279:33343-33351.
41. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
42. Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010, 115:335-343.
43. Noster R., Riedel R., Mashreghi M.F., Radbruch H., Harms L., Haftmann C., et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Translat Med 2014, 6:241ra80.
44. Di Franco M., Gerardi M.C., Lucchino B., Conti F. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. Core Evid 2014, 9:41-48.
45. Billiau A., Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009, 20:97-113.
46. Burgler S., Ouaked N., Bassin C., Basinski T.M., Mantel P.Y., Siegmund K., et al. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009, 123:588-595. 95 e1-7.
47. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
48. Lim H.W., Lee J., Hillsamer P., Kim C.H. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 2008, 180:122-129.
49. Cosmi L., De Palma R., Santarlasci V., Maggi L., Capone M., Frosali F., et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008, 205:1903-1916.
50. Fergusson J.R., Fleming V.M., Klenerman P. CD161-expressing human T cells. Front Immunol 2011, 2:36.
51. Aldemir H., Prod'homme V., Dumaurier M.J., Retiere C., Poupon G., Cazareth J., et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005, 175:7791-7795.
52. Huarte E., Cubillos-Ruiz J.R., Nesbeth Y.C., Scarlett U.K., Martinez D.G., Engle X.A., et al. PILAR is a novel modulator of human T-cell expansion. Blood 2008, 112:1259-1268.
53. Boniface K., Bak-Jensen K.S., Li Y., Blumenschein W.M., McGeachy M.J., McClanahan T.K., et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 2009, 206:535-548.
54. Kofler D.M., Marson A., Dominguez-Villar M., Xiao S., Kuchroo V.K., Hafler D.A. Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells. J Clin Invest 2014, 124:2513-2522.
55. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
56. Ciofani M., Madar A., Galan C., Sellars M., Mace K., Pauli F., et al. A validated regulatory network for Th17 cell specification. Cell 2012, 151:289-303.
57. Skepner J., Ramesh R., Trocha M., Schmidt D., Baloglu E., Lobera M., et al. Pharmacologic inhibition of RORgammat regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol 2014, 192:2564-2575.
58. Hemdan N.Y., Birkenmeier G., Wichmann G. Key molecules in the differentiation and commitment program of T helper 17 (Th17) cells up-to-date. Immunol Lett 2012, 148:97-109.
59. Maddur M.S., Miossec P., Kaveri S.V., Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012, 181:8-18.
60. Pene J., Chevalier S., Preisser L., Venereau E., Guilleux M.H., Ghannam S., et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008, 180:7423-7430.
61. Corvaisier M., Delneste Y., Jeanvoine H., Preisser L., Blanchard S., Garo E., et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 2012, 10:e1001395.
62. Raza K., Scheel-Toellner D., Lee C.Y., Pilling D., Curnow S.J., Falciani F., et al. Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther 2006, 8:R120.
63. van Hamburg J.P., Asmawidjaja P.S., Davelaar N., Mus A.M., Cornelissen F., van Leeuwen J.P., et al. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation. Ann Rheum Dis 2012, 71:606-612.
64. van Hamburg J.P., Corneth O.B., Paulissen S.M., Davelaar N., Asmawidjaja P.S., Mus A.M., et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013, 72:1700-1707.
65. Shen H., Goodall J.C., Hill Gaston J.S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009, 60:1647-1656.
66. Zhao L., Jiang Z., Jiang Y., Ma N., Zhang Y., Feng L., et al. IL-22+ CD4+ T cells in patients with rheumatoid arthritis. Int J Rheum Dis 2013, 16:518-526.
67. Komatsu N., Takayanagi H. Autoimmune arthritis: the interface between the immune system and joints. Adv Immunol 2012, 115:45-71.
68. Neumann E., Lefevre S., Zimmermann B., Gay S., Muller-Ladner U. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mole Med 2010, 16:458-468.
69. Hot A., Zrioual S., Toh M.L., Lenief V., Miossec P. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011, 70:341-348.
70. McInnes I.B., Leung B.P., Liew F.Y. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res 2000, 2:374-378.
71. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
72. Tran C.N., Lundy S.K., White P.T., Endres J.L., Motyl C.D., Gupta R., et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007, 171:1588-1598.
73. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046.
74. Ogura H., Murakami M., Okuyama Y., Tsuruoka M., Kitabayashi C., Kanamoto M., et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636.
75. Burrage P.S., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Frontiers Biosci J Virt Lib 2006, 11:529-543.
76. Brennan F.M., Hayes A.L., Ciesielski C.J., Green P., Foxwell B.M., Feldmann M. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 2002, 46:31-41.
77. Ryu S., Lee J.H., Kim S.I. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006, 25:16-20.
78. Tunyogi-Csapo M., Kis-Toth K., Radacs M., Farkas B., Jacobs J.J., Finnegan A., et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008, 58:2397-2408.
79. Shigeyama Y., Pap T., Kunzler P., Simmen B.R., Gay R.E., Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530.
80. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
81. Pollinger B., Junt T., Metzler B., Walker U.A., Tyndall A., Allard C., et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol 2011, 186:2602-2612.
82. Davignon J.L., Hayder M., Baron M., Boyer J.F., Constantin A., Apparailly F., et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013, 52:590-598.
83. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005, 174:864-870.
84. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092.
85. Bosco M.C., Puppo M., Santangelo C., Anfosso L., Pfeffer U., Fardin P., et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol 2006, 177:1941-1955.
86. Kaplan M.J. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther 2013, 15:219.
87. Wright H.L., Moots R.J., Edwards S.W. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 2014, 10:593-601.
88. Gomez-Cambronero J., Horn J., Paul C.C., Baumann M.A. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol 2003, 171:6846-6855.
89. Wright H.L., Bucknall R.C., Moots R.J., Edwards S.W. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 2012, 51:451-459.
90. Eljaafari A., Tartelin M.L., Aissaoui H., Chevrel G., Osta B., Lavocat F., et al. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum 2012, 64:2147-2157.
91. Hu F., Li Y., Zheng L., Shi L., Liu H., Zhang X., et al. Toll-like receptors expressed by synovial fibroblasts perpetuate Th1 and th17 cell responses in rheumatoid arthritis. PLoS ONE 2014, 9:e100266.
92. Hu F., Mu R., Zhu J., Shi L., Li Y., Liu X., et al. Hypoxia and hypoxia-inducible factor-1alpha provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis 2014, 73:928-936.
93. Lee D.G., Woo J.W., Kwok S.K., Cho M.L., Park S.H. MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med 2013, 45:e20.
94. Ryu J.H., Chae C.S., Kwak J.S., Oh H., Shin Y., Huh Y.H., et al. Hypoxia-inducible factor-2alpha is an essential catabolic regulator of inflammatory rheumatoid arthritis. PLoS Biol 2014, 12:e1001881.
95. Evans H.G., Gullick N.J., Kelly S., Pitzalis C., Lord G.M., Kirkham B.W., et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci USA 2009, 106:6232-6237.
96. Evans H.G., Suddason T., Jackson I., Taams L.S., Lord G.M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci USA 2007, 104:17034-17039.
97. Rossol M., Kraus S., Pierer M., Baerwald C., Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012, 64:671-677.
98. Chizzolini C., Chicheportiche R., Alvarez M., de Rham C., Roux-Lombard P., Ferrari-Lacraz S., et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008, 112:3696-3703.
99. Wan Q., Kozhaya L., ElHed A., Ramesh R., Carlson T.J., Djuretic I.M., et al. Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells. J Exp Med 2011, 208:1875-1887.
100. Sundrud M.S., Trivigno C. Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 2013, 25:263-272.
101. Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol 2014, 164:171-177.
102. Sallusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012, 42:2215-2220.
103. Basu R., O'Quinn D.B., Silberger D.J., Schoeb T.R., Fouser L., Ouyang W., et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012, 37:1061-1075.
104. Hao J.-Q. Targeting interleukin-22 in psoriasis. Inflammation 2014, 37:94-99.
105. Leipe J., Schramm M.A., Grunke M., Baeuerle M., Dechant C., Nigg A.P., et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1453-1457.
106. Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010, 107:14751-14756.
107. Cosmi L., Cimaz R., Maggi L., Santarlasci V., Capone M., Borriello F., et al. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 2011, 63:2504-2515.
108. Park J.K., Han B.K., Park J.A., Woo Y.J., Kim S.Y., Lee E.Y., et al. CD70-expressing CD4 T cells produce IFN-gamma and IL-17 in rheumatoid arthritis. Rheumatology (Oxford) 2014.
109. Zhu J., Paul W.E. Heterogeneity and plasticity of T helper cells. Cell Res 2010, 20:4-12.
110. Wei G., Wei L., Zhu J., Zang C., Hu-Li J., Yao Z., et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009, 30:155-167.
111. Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
112. Boniface K., Blumenschein W.M., Brovont-Porth K., McGeachy M.J., Basham B., Desai B., et al. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010, 185:679-687.
113. Kleinewietfeld M., Hafler D.A. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol 2013, 25:305-312.
114. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113:4240-4249.
115. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
116. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA 2009, 106:8635-8640.
117. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009, 106:4793-4798.
118. Bovenschen H.J., van de Kerkhof P.C., van Erp P.E., Woestenenk R., Joosten I., Koenen H.J. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011, 131:1853-1860.
119. Liu X., Gao N., Li M., Xu D., Hou Y., Wang Q., et al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS ONE 2013, 8:e64531.
120. Longhi M.S., Liberal R., Holder B., Robson S.C., Ma Y., Mieli-Vergani G., et al. Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology 2012, 142(1526-35):e6.
121. Ueno A., Jijon H., Chan R., Ford K., Hirota C., Kaplan G.G., et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 2013, 19:2522-2534.
122. Wang T., Sun X., Zhao J., Zhang J., Zhu H., Li C., et al. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. Ann Rheum Dis 2014.
123. Yang X.O., Nurieva R., Martinez G.J., Kang H.S., Chung Y., Pappu B.P., et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008, 29:44-56.
124. Nyirenda M.H., Sanvito L., Darlington P.J., O'Brien K., Zhang G.X., Constantinescu C.S., et al. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011, 187:2278-2290.
125. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72.
126. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013, 72:863-869.
127. Genovese M.C., Greenwald M., Cho C.S., Berman A., Jin L., Cameron G.S., et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014, 66:1693-1704.
128. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
129. Martin D.A., Churchill M., Flores-Suarez L., Cardiel M.H., Wallace D., Martin R., et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013, 15:R164.
130. Pavelka K., Kavanaugh A.F., Rubbert-Roth A., Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2012, 51(Suppl 5). v12-21.
131. Huh J.R., Littman D.R. Small molecule inhibitors of RORgammat: targeting Th17 cells and other applications. Eur J Immunol 2012, 42:2232-2237.
132. Xiao S., Yosef N., Yang J., Wang Y., Zhou L., Zhu C., et al. Small-molecule RORgammat antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014, 40:477-489.
133. Wilder E.G., Patel M., Hebeler K., Menter A. Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. J Drugs Dermatol 2014, 13:905-910.
134. Song G.G., Bae S.C., Lee Y.H. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol 2012, 31:1733-1739.
135. Gopinath K., Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis 2011, 14:332-339.
136. Colin E.M., Asmawidjaja P.S., van Hamburg J.P., Mus A.M., van Driel M., Hazes J.M., et al. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010, 62:132-142.
137. Alzabin S., Abraham S.M., Taher T.E., Palfreeman A., Hull D., McNamee K., et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann Rheum Dis 2012, 71:1741-1748.
138. Aerts N.E., De Knop K.J., Leysen J., Ebo D.G., Bridts C.H., Weyler J.J., et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 2010, 49:2264-2272.
139. Page T.H., Turner J.J., Brown A.C., Timms E.M., Inglis J.J., Brennan F.M., et al. Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol 2010, 185:3694-3701.
140. Steinfelder S., Floess S., Engelbert D., Haeringer B., Baron U., Rivino L., et al. Epigenetic modification of the human CCR6 gene is associated with stable CCR6 expression in T cells. Blood 2011, 117:2839-2846.
141. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Aelion J.A., et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014, 41:414-421.
142. de Jong P.H., Hazes J.M., Han H.K., Huisman M., van Zeben D., van der Lubbe P.A., et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014, 73:1331-1339.
143. Bottini N., Firestein G.S. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep 2013, 15:372.
144. Baumjohann D., Ansel K.M. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol 2013, 13:666-678.
145. Hu G., Tang Q., Sharma S., Yu F., Escobar T.M., Muljo S.A., et al. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat Immunol 2013, 14:1190-1198.
146. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
147. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
148. Sutton C.E., Mielke L.A., Mills K.H. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol 2012, 42:2221-2231.
149. Fogel L.A., Yokoyama W.M., French A.R. Natural killer cells in human autoimmune disorders. Arthritis Res Ther 2013, 15:216.